2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

4:30PM-6:00PM: Abstract Number: 1854

The Utility of Fat Lesions in Close Relation to Other Structural MRI Lesions in the Sacroiliac Joints for Diagnosing Patients with Axial Spondyloarthritis

4M111: Imaging of Rheumatic Diseases I (1854–1859)

4:30PM-6:00PM: Abstract Number: 1862

Treat to Target Opportunities – Design, Testing, and Adoption of a Novel EHR-Integrated Electronic System to Engage Rheumatologists and Capture Decision Making

4M112: Measures of Healthcare Quality I: Digital Health Technologies – Tool for Improvement (1860–1865)

4:30PM-6:00PM: Abstract Number: 1917

Tubulointerstitial Inflammation Predicts Outcomes in Lupus Nephritis

4M120: SLE – Clinical IV: Lupus Nephritis (1914–1919)

4:30PM-6:00PM: Abstract Number: 1918

Urine CD163 Significantly Discriminates Active Lupus Nephritis and Strongly Correlates with Proliferative Glomerulonephritis

4M120: SLE – Clinical IV: Lupus Nephritis (1914–1919)

4:30PM-6:00PM: Abstract Number: 1861

Use of a Novel Electronic Auto-notification Process to Manage Transitions of Care in Rheumatic Patients on DMARD Therapy

4M112: Measures of Healthcare Quality I: Digital Health Technologies – Tool for Improvement (1860–1865)

4:30PM-6:00PM: Abstract Number: 1860

Using Electronic Visits (E-Visits) to Achieve Goal Serum Urate Levels in Patients with Gout in a Rheumatology Practice: A Pilot Study

4M112: Measures of Healthcare Quality I: Digital Health Technologies – Tool for Improvement (1860–1865)

4:30PM-6:00PM: Abstract Number: 1906

Using Multi-modal Ultrasound to Assess Disease Activity Within the Salivary Glands of Patients with Primary Sjögren’s Syndrome Treated with Ianalumab (VAY736)

4M119: Sjögrenʼs Syndrome – Basic & Clinical Science (1902–1907)

4:30PM-6:00PM: Abstract Number: 1915

Validation of a Serologic Antibody Biomarker Against a Candidate Gut Pathobiont for the Diagnosis of Lupus Nephritis

4M120: SLE – Clinical IV: Lupus Nephritis (1914–1919)

4:30PM-6:00PM: Abstract Number: 1872

Worsening Trends in Osteoporosis Management in the Medicare Population: 2010-2014

4M114: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (1872–1877)

Tuesday, November 12, 2019

9:00AM-11:00AM: Abstract Number: 2045

RNA Sequencing of Plasma and Urine-derived Extracellular Vesicles from Lupus Nephritis Patients Identifies Disease-associated Small RNA Signatures and Putative Therapeutic Targets

SLE – Etiology & Pathogenesis Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].